Table 3

Secondary end points five days after enrolment and changes from baseline values according to treatment group

At day 5Crude change from baseline
End pointsSteroid* (No of missing data)Placebo* (No of missing data)Steroid (n=43)Placebo (n=42)Treatment effect (95% CI)
*Missing data are handled by applying an LOCF procedure (last observation carried forward). Results are expressed as means (SD) calculated once the LOCF procedure has been applied. We also specify the number of missing data in each group.
†A positive value means improvement.
Pain VAS (mm)31.0 (20.8)(2)34.5 (19.8)(2)−25.3 (26.1)−21.8 (20.7)−3.5(−13.5 to 6.5)
Schober’test (cm)†2.69 (1.02)(7)2.64 (0.99)(5)0.45 (1.00)0.45 (0.93)0.01(−0.41 to 0.42)
SLR test (degree)†60.1 (17.5)(2)55.3 (20.3)(3)14.4 (20.9)9.5 (15.8)4.9(−3.0 to 12.8)
Dallas pain questionnaire:
    Daily activities46.1 (24.9)(3)51.6 (21.3)(2)−16.7 (24.1)−16.6 (21.4)−0.2(−9.9 to 9.5)
    Work-leisure activities57.4 (31.2)(9)64.9 (20.1)(7)−10.6 (27.0)−10.4 (17.8)−0.2(−9.9 to 9.5)
    Anxiety-depression21.7 (24.8)(2)28.0 (24.2)(1)−6.0 (32.5)−6.1 (22.5)0.0(−11.8 to 11.9)
    Social interest19.7 (20.4)(3)26.0 (20.1)(2)−7.6 (19.1)−0.5 (14.4)−7.1(−14.3 to 0.1)
Roland-Morris index12.6 (5.2)(2)12.8 (4.3)(1)−2.6 (6.1)−1.2 (5.4)−1.3(−3.8 to 1.1)